Use of colony-stimulating factors with chemotherapy: Opportunities for cost savings and improved outcomes

Journal of the National Cancer Institute

Volumn 103, Issue 12, 2011, Pages 979-982

  Potosky, Arnold L ^a   Malin, Jennifer L ^b   Kim, Benjamin ^b   Chrischilles, Elizabeth A ^b   Makgoeng, Solomon B ^b   Howlader, Nadia ^b   Weeks, Jane C ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COMORBIDITY; COST CONTROL; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLONY-STIMULATING FACTORS; COLORECTAL NEOPLASMS; COST SAVINGS; DRUG PRESCRIPTIONS; EVIDENCE-BASED MEDICINE; FEMALE; FEVER; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79959745514     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr152     Document Type: Article

References (18)

1. Heuser M, Ganser A, Bokemeyer C; American Society of Clinical Oncology; National Comprehensive CN; European Organization for Research and Treatment of Cancer. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. Semin Hematol. 2007;44(3):148-156.
2. Hershman D, Hurley D, Wong M, Morrison VA, Malin JL. Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ. 2009;12(3):203-210.
3. Bennett CL, Somerfield MR, Pfister DG, et al. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol. 2003; 21(5):937-941. (Pubitemid 46606456)
4. Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18(8):1764-1770. (Pubitemid 30220556)
5. Naiem A, Friedman L, Pasta DJ, et al. Prophylaxis of chemotherapy-induced neutropenia: patterns of care in U.S. community oncology practices [2007 ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2007;25(18S):9123.
6. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999;17(11): 3676-3681. (Pubitemid 29517939)
7. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205. (Pubitemid 46638957)
8. Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5(2):188-202. (Pubitemid 46423058)
9. McNeil C. NCCN guidelines advocate wider use of colony-stimulating factor. J Natl Cancer Inst. 2005;97(10):710-711. (Pubitemid 40872371)
10. Ramsey SD, McCune JS, Blough DK, et al. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care. 2010;16(9): 678-686.
11. Ayanian JZ, Chrischilles EA, Fletcher RH, et al. Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol. 2004;22(15):2992-2996.
12. Catalano PJ, Ayanian JZ, Harrington DP, Kahn KL, Landrum MB, Zaslavsky AM. Representativeness of the CanCORS participants relative to Surveillance, Epidemiology & End Results (SEER) cancer registries. Paper presented at Academy Health Annual Research meeting; June 8, 2008; Washington, DC.
13. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-2447. (Pubitemid 38669187)
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Myeloid Growth Factors Guidelines, Version 1; 2009. Fort Washington, PA.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
16. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg. 2002;128(10):1172-1179. (Pubitemid 35168108)
17. Yim JM, Matuszewski KA, Vermeulen LC Jr., Ratko TA, Burnett DA, Vlasses PH. Surveillance of colony-stimulating factor use in US academic health centers. Ann Pharmacother. 1995;29(5):475-481.
18. Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(4): 620-627.